Skip to content
  • There are no suggestions because the search field is empty.
  • There are no suggestions because the search field is empty.
Press Release

RapidAI Receives FDA Clearance for Rapid Hyperdensity

RapidAI announced it has received FDA clearance for Rapid Hyperdensity, the newest addition to the RapidAI platform

Share to

RapidAI announced it has received FDA clearance for Rapid Hyperdensity, the newest addition to the RapidAI platform

San Mateo, Calif. — July 21 , 2022 — RapidAI , the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow, today announced it has received FDA clearance for Rapid Hyperdensity , the newest addition to the RapidAI platform. The tool empowers physicians to quickly assess the severity of injury in patients with acute neuro conditions such as traumatic brain injury and brain hemorrhages – allowing for better and faster patient care decisions. Powered by AI, Rapid Hyperdensity uses non-contrast CT scans to quickly assess the volume of hyperdense tissue in the brain to help physicians identify the extent of an intracerebral hemorrhage which is crucial for patient treatment decisions. For hospitals and mobile stroke units on the front lines of patient assessment, Rapid Hyperdensity provides additional contextual data to help physicians make more informed triage and transfer decisions–getting patients to the right place more efficiently. “Rapid Hyperdensity helps physicians make the first of many critical decisions involved in head trauma and hemorrhagic stroke protocol. As the only comprehensive neurovascular decision support platform to offer this functionality, RapidAI aims to alleviate the enormous pressure of determining the best next course of action , ” said Karim Karti, CEO of RapidAI. “This FDA clearance is a symbol of RapidAI’s ongoing commitment to push the boundaries of neurovascular care, while designing every product with physicians first in mind.” The key benefits of Rapid Hyperdensity include: Automated detection of intracranial hyperdensities >1ml Quick identification of hyperdense volumes to improve hemorrhage management Fast results that can be viewed via the Rapid mobile app, PACS/Workstation, or email "As a neurosurgeon who treats many patients with intracranial hemorrhage (ICH), I am very excited for the recently approved Rapid Hyperdensity product that builds on the well-established RapidAI stroke platform,” said Dr. Alejandro M. Spiotta, director of the Neuroendovascular Surgery Division at the Medical University of South Carolina. “Detection of ICH via AI can save lives by helping to speed up diagnosis and accelerate transfer to the best physician and hospital that can take care of the patient. With the addition of automatic hyperdense volume measurement, physicians can more easily track volume over time and help quickly identify which patients may require an intervention. This is an exciting time for those of us treating ICH." To learn more about how RapidAI is transforming stroke care, please visit: https://www.rapidai.com/stroke About RapidAI RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions. Empowering physicians to make faster decisions for better patient outcomes, RapidAI is leading the next evolution of clinical decision-making and patient workflow. Based on intelligence gained from over 5 million scans in more than 2,000 hospitals in over 60 countries, the Rapid® platform transforms care coordination, offering care teams a level of patient visibility never before possible. RapidAI – where AI meets patient care.

Contact PR

Jessica Stebing

Jessica Stebing

Group Manager, Marketing Communications

stebing@rapidai.com